Teva Pharmaceutical Industries Limited (NYSE:TEVA) saw unusually large options trading activity on Wednesday. Stock traders purchased 33,257 call options on the company. This represents an increase of 111% compared to the average volume of 15,733 call options.

Large investors have recently modified their holdings of the business. San Francisco Sentry Investment Group CA bought a new position in shares of Teva Pharmaceutical Industries Limited during the second quarter worth about $106,000. Kistler Tiffany Companies LLC grew its position in shares of Teva Pharmaceutical Industries Limited by 74.7% during the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after acquiring an additional 1,571 shares during the last quarter. Bronfman E.L. Rothschild L.P. grew its position in shares of Teva Pharmaceutical Industries Limited by 2.6% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after acquiring an additional 94 shares during the last quarter. FNY Managed Accounts LLC bought a new position in shares of Teva Pharmaceutical Industries Limited during the first quarter worth about $123,000. Finally, Sterling Investment Advisors Ltd. grew its position in shares of Teva Pharmaceutical Industries Limited by 2.6% during the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after acquiring an additional 100 shares during the last quarter. 56.77% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 15.94 on Friday. The firm’s 50-day moving average is $16.91 and its 200 day moving average is $26.76. The stock’s market capitalization is $16.20 billion. Teva Pharmaceutical Industries Limited has a 12 month low of $15.22 and a 12 month high of $45.85.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.06 by ($0.07). The business had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The firm’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same period last year, the company posted $1.25 earnings per share. On average, equities analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.28 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th were issued a dividend of $0.085 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $0.34 dividend on an annualized basis and a dividend yield of 2.13%. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is -15.36%.

A number of equities research analysts have issued reports on TEVA shares. Vetr upgraded shares of Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating and set a $32.27 target price on the stock in a report on Wednesday, June 28th. Royal Bank Of Canada reiterated an “outperform” rating and set a $37.00 target price (down from $38.00) on shares of Teva Pharmaceutical Industries Limited in a report on Monday, July 17th. Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries Limited from a “strong sell” rating to a “hold” rating in a report on Wednesday. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and set a $21.00 target price (down from $28.00) on shares of Teva Pharmaceutical Industries Limited in a report on Thursday, August 31st. Finally, BTIG Research upgraded shares of Teva Pharmaceutical Industries Limited from a “neutral” rating to a “buy” rating and set a $24.00 target price on the stock in a report on Monday, September 11th. Five analysts have rated the stock with a sell rating, eighteen have given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $28.72.

WARNING: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/10/07/teva-pharmaceutical-industries-limited-sees-unusually-large-options-volume-teva.html.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.